Cat. No.: DAB-0012720
Product Information | |
---|---|
Clonality | Monoclonal |
Isotype | IgG |
Host Species | Rabbit |
Reactivity | Human, Mouse, Rat, Monkey, Bovine |
Applications | WB, IP |
Product Description | Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ala880 of human PKD3/PKCν protein. |
Format | Liquid |
Purity | Affinity purity |
Target Information | |
---|---|
Target Name | PRKD3 |
UniProt No. | O94806 |
Gene ID | 23683 |
Gene Description | PKCν, also known as PKD3, is a member of the protein kinase C family of serine/threonine kinases that play critical roles in the regulation of cellular differentiation and proliferation. PKCν is composed of 890 amino acid residues and has 77.3% similarity to human PKCμ and 77. 4% similarity to mouse PKD. The PKCν mRNA is ubiquitously expressed in various tissues. PKCν has two putative diacylglycerol binding C1 domains, suggesting that it may participate in a novel diacylglycerol-mediated signaling pathway. PKCν is translocated to the plasma membrane and activated by the diacylglycerol mimic phorbol 12-myristate 13-acetate. PKCν is an important physiologic target of the B-cell receptor and exhibits robust activation after BCR engagement. GPCR agonists induce a rapid activation of PKCν by a protein kinase C -dependent pathway that leads to the phosphorylation of the activation loop of PKCν. PKCν is present both in the nucleus and cytoplasm and this distribution of PKCν results from its continuous shuttling between both compartments by a mechanism that requires a nuclear import receptor and a competent CRM1-nuclear export pathway. Cell stimulation with the GPCR agonist neurotensin induces a rapid and reversible plasma membrane translocation of PKCν that is PKC-dependent. |
Shipping & Storage | |
---|---|
Shipping | Shipped at 4 °C. |
Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.